Civica Rx, a non-profit company, has received a lot of attention from hospitals in the US who want to combat the stockpile problems of high drug prices.
For years, healthcare systems have charged exorbitant prices for drugs delivered through injections or solutions. According to the American Health System Pharmacists Association currently facing shortage of supply 205 drugs there is. This list includes everything from saline solution bags to common antibiotics to a type of epidural used for pregnant women during childbirth.
Some drug shortages are related to production problems, sometimes companies that produce the drug stop production or a drug is produced by only one company. at high price is sold.
Hospitals now have a plan to combat this situation. Civica Rx The nonprofit first emerged in early 2018 and has received a lot of attention from hospitals in the US who want to be a part of this initiative.
Recently, the organization has joined the likes of Illinois and Wisconsin-based Advocate Aurora Health, Michigan Spectrum Health, and NYU Langone Health. 12 health systems joined. Also, the initiative 250 hospitals more added. Catholic Health Initiatives, HCA Healthcare, Intermountain Healthcare, Mayo Clinic, and Providence St. Many hospitals, such as Joseph Health, are participating in the project. Civica will initially focus on producing 14 drugs, mostly injectables, used in hospitals. These are expected to be produced in 2019. Among the company’s priorities is the FDA’s supply shortage essential drugs on the list of drugs that are sold at high prices It also includes manufacturing medicines.
Source: Business Insider
Civica Rx, the non-profit company of which Martin VanTrieste is the CEO, first appeared in early 2018. The initiative has garnered a lot of attention from hospitals in the US, who want to combat the high prices and frequent shortages of drugs. 12 health systems and 250 hospitals are participating in the project. In 2019, Civica will focus on producing 14 drugs, mostly injectables, used in hospitals. The company’s priorities include producing essential drugs on the FDA’s list of drugs with supply shortages, and drugs that are sold at high prices because there is no competition.